Pharmaceutical Technology: Controlled Drug Release, Volume 2

More documents

Recommendations

Info

CH. 5] AN OPTIMIZED PROLONGED RELEASE FORMULATION 61 Table 2—Optimized process results (2) Is porosity associated with the dissolution profile, and with one of the studied parameters? (3) As the AUC value is almost the same, may the β parameter of the Weibull function be used for evaluating the variability between tablets and between processes? The flowability test The flowability test was carried out in a Jenike cell [3,13]. The flow function illustrated in Fig. 1 reveals a singular behaviour of the powders which may be associated with the process or with the high percentage of PVC. In fact, even if the curves were obtained by linear regression, a marked dispersion may be seen, particularly for the compaction of the mixture and, curiously, for the wet granulation powder. Regarding the flow function values, powders may be classed in two groups: (1) the direct compression powder, representing poor flow; (2) the granulated powders, giving easy flow. Because of this singular behaviour of the powders, it was supposed that the powder blends were not homogeneous even though the variability of the tablet weight was at a minimum. This means that the test is very sensitive to the technological modifications of the same formula.
62 MATRIX FORMULATIONS [CH. 5 Fig. 1—Flow function and flowability (ic) of the optimized formulations. The porosimetry measurements In order to characterize the microstructure of the matrices, the total porosimetry factor, the pore volume, the pore surface and the mean pore diameter were measured using a mercury porosimeter (Micrometrics) [3]. The mean of three replicates and their coefficient of variation are indicated in Table 3. From the results, it is possible to draw the following conclusions. (1) In accordance with the Dubinin classification [14], all the matrix tablets exhibited macropores (mean pore diameter >200Å). (2) The tablets obtained by direct compression in a single punch machine (Frogerais) and those obtained by wet granulation had very similar values; only the coefficient of variation differentiate these two processes. (3) As expected, as the applied UPF increased, the porosimetry parameters decreased (UPF values: direct compression and wet granulation, 7 kN; double compression, 12 kN; separate compaction, 19 kN; compaction of the mixture, 31 kN). (4) The variability of the porosity parameters may be used to differentiate the processes. It also explains the variability of the dissolution parameters because of the same order of variation (CV): wet granulation (3.0)
Page 2 and 3:
PHARMACEUTICAL TECHNOLOGY Controlle
Page 4 and 5:
3 TABLET MACHINE INSTRUMENTATION IN
Page 6 and 7:
First published in 1991 by ELLIS HO
Page 8 and 9:
7 10 Controlled delivery of theophy
Page 10:
Slow and steady wins the race Poems
Page 14 and 15: 1 Influence of drug solubility in t
Page 16 and 17: CH. 1] INFLUENCE OF DRUG SOLUBILITY
Page 22: CH. 1] INFLUENCE OF DRUG SOLUBILITY
Page 25 and 26: 24 MATRIX FORMULATIONS [CH. 2 MATER
Page 27 and 28: 26 MATRIX FORMULATIONS [CH. 2 Fig.
Page 29 and 30: 28 MATRIX FORMULATIONS [CH. 2 Table
Page 31 and 32: 30 MATRIX FORMULATIONS [CH. 2 The e
Page 35 and 36: 34 CH. 3] THE FORMULATION OF SUSTAI
Page 44 and 45: 4 Statistical optimization of a con
Page 46 and 47: MATRIX FORMULATIONS [CH. 4 45 (4) G
Page 48 and 49: MATRIX FORMULATIONS [CH. 4 47 Fig.
Page 50 and 51: Columns 1-4 lead to the matrix of e
Page 52 and 53: MATRIX FORMULATIONS [CH. 4 51 Table
Page 54 and 55: MATRIX FORMULATIONS [CH. 4 53 Fig.
Page 56: Fig. 5—Linearization of the relea
Page 59 and 60: 58 MATRIX FORMULATIONS [CH. 5 Pevik
Page 61: 60 MATRIX FORMULATIONS [CH. 5 The d
Page 72 and 73: 6 Controlled release matrix tablets
Page 74 and 75: CH. 6] CONTROLLED RELEASE MATRIX TA
Page 80 and 81: 7 A new ibuprofen pulsed release or
Page 82 and 83: CH. 7] A NEW IBUPROFEN PULSED RELEA
Page 88: CH. 7] A NEW IBUPROFEN PULSED RELEA
Page 91 and 92: 90 CH. 8] TOPICAL RELEASE AND PERME
Page 101 and 102: 100
Page 103 and 104: 102
Page 105 and 106: 104 MULTIPARTICULATES [CH. 9 parace
Page 107 and 108: 106 MULTIPARTICULATES [CH. 9 (a) th
Page 109 and 110: 108 MULTIPARTICULATES [CH. 9 Fig. 2
Page 111 and 112: 110 MULTIPARTICULATES [CH. 9 Fig. 6
Page 113 and 114:
112 MULTIPARTICULATES [CH. 9 Fig. 7
Page 115 and 116:
114 MULTIPARTICULATES [CH. 9 Fig. 8
Page 117 and 118:
116
Page 119 and 120:
118 CH. 10] CONTROLLED DELIVERY OF
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
126 CH. 11] THE EFFECT OF FOOD ON G
Page 129 and 130:
128 CH. 11] THE EFFECT OF FOOD ON G
Page 131 and 132:
130
Page 133 and 134:
132 CH. 12] BIODEGRADABLE POLYMERS
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
140
Page 143 and 144:
142 CH. 13] A COMPARISON OF DISSOLU
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
152
Page 155 and 156:
154
Page 157 and 158:
156 OPHTHALMIC FORMULATION [CH. 14
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
162 CH. 15] A SUSTAINED RELEASE OPH
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
170
Page 173 and 174:
172 IMPLANTS [CH. 16 The purpose of
Page 175 and 176:
174 IMPLANTS [CH. 16 times with 5 m
Page 177 and 178:
176 IMPLANTS [CH. 16 noted that the
Page 179 and 180:
178 IMPLANTS [CH. 16 Fig. 1—The e
Page 181 and 182:
180 IMPLANTS [CH. 16 Table 3—Tobr
Page 183 and 184:
182
Page 185 and 186:
184 CH. 17] SILICON MATRIX SYSTEMS
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
192
Page 195 and 196:
194 INDEX dry granulation, 43 elect
show all

Pharmaceutical Technology: Controlled Drug Release, Volume 2

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?